Sofosbuvir — Discount Pricing

Other medications in Infections

• Tedizolid
• Tenofovir
• Terbinafine
• Tetracycline
• Tigecycline
• Trimethoprim-Sulfamethoxazole
• Valacyclovir
• Valganciclovir

About Sofosbuvir

Sofosbuvir is a powerful antiviral medication revolutionizing the treatment of chronic Hepatitis C. Its introduction has offered new hope to millions. For those facing the high costs associated with such advanced therapies, TheDrugClub offers a vital resource, helping members access potential savings and discounted pricing on essential medications like sofosbuvir.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Sofosbuvir is approved for (FDA label)

SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of: Adult patients with genotype 1, 2, 3 or 4 chronic HCV infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen. ( 1 ) Pediatric patients 3 years of age and older with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin. ( 1 ) Adult Patients: SOVALDI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection as a component of a combination antiviral treatment regimen [see Dosage and Administration (2.2) , and Clinical Studies (14) ]: genotype 1 or 4 infection without cirrhosis or with compensated cirrhosis for use in combination with pegylated interferon and ribavirin genotype 2 or 3 infection without cirrhosis or with compensated cirrhosis for use in combination with ribavirin.

Source: Read the full FDA label on DailyMed. Label effective date: December 26, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Sofosbuvir (FDA label)

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with SOVALDI. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions (5.1) ] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 80beab2c-396e-4a37-a4dc-40fdb62859cf. SPL document ID: 74c52ec6-8358-4e63-b299-64ec1ff7f434. Label effective date: December 26, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Sofosbuvir (FDA label)

SOVALDI is available as tablets or pellets for oral use. Each dosage form is available in two dose strengths. 400 mg Tablets: 400 mg sofosbuvir: yellow, capsule-shaped, film-coated tablet debossed with "GSI" on one side and "7977" on the other side. 200 mg Tablets: 200 mg sofosbuvir: yellow, oval-shaped, film-coated tablet debossed with "GSI" on one side and "200" on the other side. 200 mg Pellets: 200 mg sofosbuvir: white to off-white pellets in unit-dose packets. 150 mg Pellets: 150 mg sofosbuvir: white to off-white pellets in unit-dose packets. Tablets: 400 mg and 200 mg of sofosbuvir. ( 3 ) Oral Pellets: 200 mg and 150 mg of sofosbuvir. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 80beab2c-396e-4a37-a4dc-40fdb62859cf. SPL document ID: 74c52ec6-8358-4e63-b299-64ec1ff7f434. Label effective date: December 26, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Sofosbuvir (FDA label)

The following serious adverse reactions are described below and elsewhere in the labeling: Serious Symptomatic Bradycardia When Coadministered with Amiodarone [see Warnings and Precautions (5.2) ] . The most common adverse events (incidence greater than or equal to 20%, all grades) observed with SOVALDI in combination with ribavirin were fatigue and headache. The most common adverse events observed with SOVALDI in combination with peginterferon alfa and ribavirin were fatigue, headache, nausea, insomnia and anemia. ( 6.1 ).

Source: FDA prescribing information (DailyMed). Set ID: 80beab2c-396e-4a37-a4dc-40fdb62859cf. SPL document ID: 74c52ec6-8358-4e63-b299-64ec1ff7f434. Label effective date: December 26, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Sofosbuvir (FDA label)

When SOVALDI is used in combination with ribavirin or peginterferon alfa/ribavirin, the contraindications applicable to those agents are applicable to combination therapies. Refer to the prescribing information of peginterferon alfa and ribavirin for a list of their contraindications. When used in combination with peginterferon alfa/ribavirin or ribavirin alone, all contraindications to peginterferon alfa and/or ribavirin also apply to SOVALDI combination therapy. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 80beab2c-396e-4a37-a4dc-40fdb62859cf. SPL document ID: 74c52ec6-8358-4e63-b299-64ec1ff7f434. Label effective date: December 26, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.